Magrolimab

Summary

Magrolimab (CHEMBL4297985) is a phase-3 clinical-stage antibody targeting CD47; indicated across 18 conditions including myelodysplastic syndrome and acute myeloid leukemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (CD47)
• Indications: 18 conditions
• Clinical trials: 33

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297985
Name	Magrolimab
Type	Antibody
Max phase	3

Also known as: Hu5f9 g4, Magrolimab, MAGROLIMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CD47	CD47	Binding	11.1	0.3%	Q08722

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CD47.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
Hemostasis	1	CD47
Extracellular matrix organization	1	CD47
Cell-Cell communication	1	CD47
Innate Immune System	1	CD47
Immune System	1	CD47
Cell surface interactions at the vascular wall	1	CD47
Integrin cell surface interactions	1	CD47
Signal regulatory protein family interactions	1	CD47
Neutrophil degranulation	1	CD47

Dominant GO biological processes

GO term	Targets
angiogenesis	1
apoptotic process	1
inflammatory response	1
integrin-mediated signaling pathway	1
positive regulation of cell population proliferation	1
cell migration	1
positive regulation of cell-cell adhesion	1
regulation of type II interferon production	1
regulation of interleukin-10 production	1
regulation of interleukin-12 production	1
regulation of interleukin-6 production	1
regulation of tumor necrosis factor production	1
regulation of nitric oxide biosynthetic process	1
positive regulation of inflammatory response	1
negative regulation of phagocytosis	1

Indications & clinical

Indications

18 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
myelodysplastic syndrome	3	MONDO:0018881	EFO:0000198
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222
diffuse large B-cell lymphoma	2	MONDO:0018905	EFO:0000403
neoplasm	2	MONDO:0005070	EFO:0000616
Hodgkins lymphoma	2	MONDO:0004952	MONDO:0009348
head and neck squamous cell carcinoma	2	MONDO:0010150	EFO:0000181
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
triple-negative breast carcinoma	2	MONDO:0005494	EFO:0005537
urothelial carcinoma	1	MONDO:0040679	EFO:0008528
ovarian cancer	1	MONDO:0008170	MONDO:0008170
lymphoid neoplasm	1	MONDO:0005157	EFO:0001642
non-Hodgkin lymphoma	1	MONDO:0018908	EFO:0005952
Sezary syndrome	1	MONDO:0017844	EFO:1000785
brain cancer	1	MONDO:0001657	MONDO:0001657
brain neoplasm	1	MONDO:0021211	EFO:0003833
colorectal neoplasm	1	MONDO:0005335	MONDO:0005575

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 33.

Phase distribution

Phase	Trials
PHASE1	12
PHASE2	11
PHASE1/PHASE2	6
PHASE3	3
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04313881	PHASE3	TERMINATED	Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
NCT04778397	PHASE3	TERMINATED	Study of Magrolimab in Combination With Azacitidine Versus Physician’s Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
NCT05079230	PHASE3	TERMINATED	Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
NCT04788043	PHASE2	ACTIVE_NOT_RECRUITING	Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
NCT02953509	PHASE1/PHASE2	TERMINATED	Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
NCT02953782	PHASE1/PHASE2	COMPLETED	Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
NCT03869190	PHASE1/PHASE2	COMPLETED	Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
NCT04435691	PHASE1/PHASE2	TERMINATED	Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
NCT04541017	PHASE1/PHASE2	TERMINATED	Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
NCT04778410	PHASE2	TERMINATED	Study of Magrolimab Combinations in Participants With Myeloid Malignancies
NCT04827576	PHASE2	TERMINATED	Study of Magrolimab in Patients With Solid Tumors
NCT04854499	PHASE2	TERMINATED	Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
NCT04892446	PHASE2	TERMINATED	Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
NCT04958785	PHASE2	TERMINATED	Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT05330429	PHASE2	TERMINATED	Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
NCT05367401	PHASE1/PHASE2	WITHDRAWN	A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
NCT05829434	PHASE2	WITHDRAWN	Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS
NCT05835011	PHASE2	TERMINATED	A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
NCT05929716	PHASE2	WITHDRAWN	An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
NCT06046482	PHASE2	TERMINATED	Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
NCT02216409	PHASE1	COMPLETED	Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
NCT02678338	PHASE1	COMPLETED	CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
NCT03248479	PHASE1	TERMINATED	Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
NCT03527147	PHASE1	COMPLETED	Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma (PRISM Study)
NCT03558139	PHASE1	COMPLETED	Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy
NCT03922477	PHASE1	TERMINATED	A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
NCT04599634	PHASE1	COMPLETED	Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
NCT04751383	PHASE1	COMPLETED	Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
NCT05169944	PHASE1	COMPLETED	Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
NCT05738161	PHASE1	WITHDRAWN	Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma
NCT05807126	PHASE1	WITHDRAWN	Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
NCT05823480	PHASE1	WITHDRAWN	Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
NCT05627466	Not specified	NO_LONGER_AVAILABLE	US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

98 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
.gamma.-aminobutyric acid	PubChem	Approved	CD47
Acetazolamide	PubChem	Approved	CD47
acetylcysteine	PubChem	Approved	CD47
Acyclovir	PubChem	Approved	CD47
alfaxalone	PubChem	Approved	CD47
Alfuzosin	PubChem	Approved	CD47
Allopurinol	PubChem	Approved	CD47
Amantadine	PubChem	Approved	CD47
Amiloride	PubChem	Approved	CD47
Amiodarone	PubChem	Approved	CD47
Amisulpride	PubChem	Approved	CD47
Amitriptyline	PubChem	Approved	CD47
Amoxapine	PubChem	Approved	CD47
Apraclonidine	PubChem	Approved	CD47
Aspirin	PubChem	Approved	CD47
Atenolol	PubChem	Approved	CD47
Azathioprine	PubChem	Approved	CD47
Azelaic Acid	PubChem	Approved	CD47
Baclofen	PubChem	Approved	CD47
Betaxolol	PubChem	Approved	CD47
Bethanechol	PubChem	Approved	CD47
Bicalutamide	PubChem	Approved	CD47
Brimonidine	PubChem	Approved	CD47
Bromocriptine	PubChem	Approved	CD47
Bumetanide	PubChem	Approved	CD47
Buspirone	PubChem	Approved	CD47
Caffeine	PubChem	Approved	CD47
Carbamazepine	PubChem	Approved	CD47
carbamoylcholine	PubChem	Approved	CD47
Carmustine	PubChem	Approved	CD47
Carvedilol	PubChem	Approved	CD47
Celecoxib	PubChem	Approved	CD47
Chlorothiazide	PubChem	Approved	CD47
Chlorpromazine	PubChem	Approved	CD47
Chlorzoxazone	PubChem	Approved	CD47
Cilostazol	PubChem	Approved	CD47
Cimetidine	PubChem	Approved	CD47
Citalopram	PubChem	Approved	CD47
Clomipramine	PubChem	Approved	CD47
Clonidine	PubChem	Approved	CD47
Clotrimazole	PubChem	Approved	CD47
Clozapine	PubChem	Approved	CD47
Cortisone	PubChem	Approved	CD47
Cyclobenzaprine	PubChem	Approved	CD47
cyclophosphamide	PubChem	Approved	CD47
Cyproheptadine	PubChem	Approved	CD47
dalfampridine	PubChem	Approved	CD47
Desipramine	PubChem	Approved	CD47
Dexchlorpheniramine	PubChem	Approved	CD47
Diazoxide	PubChem	Approved	CD47
Dicyclomine	PubChem	Approved	CD47
Diphenhydramine	PubChem	Approved	CD47
Dipyridamole	PubChem	Approved	CD47
Disopyramide	PubChem	Approved	CD47
Disulfiram	PubChem	Approved	CD47
Domperidone	PubChem	Approved	CD47
Doxazosin	PubChem	Approved	CD47
Doxylamine	PubChem	Approved	CD47
Epinastine	PubChem	Approved	CD47
Eslicarbazepine	PubChem	Approved	CD47